X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (42) 42
humans (40) 40
melanoma (35) 35
oncology (30) 30
animals (28) 28
cell line, tumor (23) 23
mice (23) 23
article (22) 22
cancer (22) 22
melanoma - pathology (20) 20
cell biology (19) 19
melanoma - genetics (18) 18
female (16) 16
melanoma - drug therapy (16) 16
braf (14) 14
metastatic melanoma (14) 14
acquired-resistance (13) 13
drug resistance (12) 12
proto-oncogene proteins b-raf - antagonists & inhibitors (12) 12
proto-oncogene proteins b-raf - genetics (12) 12
melanoma - metabolism (11) 11
xenograft model antitumor assays (11) 11
indoles - pharmacology (10) 10
mutation (10) 10
mutations (10) 10
dermatology (9) 9
metastasis (9) 9
protein kinase inhibitors - pharmacology (9) 9
sulfonamides - pharmacology (9) 9
biology (8) 8
immunotherapy (8) 8
kinases (8) 8
signal transduction - drug effects (8) 8
survival (8) 8
therapy (8) 8
vemurafenib (8) 8
activation (7) 7
antineoplastic agents - pharmacology (7) 7
growth (7) 7
male (7) 7
mek (7) 7
metastases (7) 7
neoplasms (7) 7
patients (7) 7
resistance (7) 7
analysis (6) 6
antineoplastic agents - therapeutic use (6) 6
cell lines (6) 6
cells (6) 6
drug resistance, neoplasm (6) 6
inhibition (6) 6
mek inhibitors (6) 6
mice, scid (6) 6
multidisciplinary sciences (6) 6
phosphorylation (6) 6
proto-oncogene proteins b-raf - metabolism (6) 6
research article (6) 6
skin neoplasms - genetics (6) 6
skin neoplasms - pathology (6) 6
tumors (6) 6
apoptosis (5) 5
cell proliferation - drug effects (5) 5
drug resistance, neoplasm - drug effects (5) 5
expression (5) 5
gene knockdown techniques (5) 5
inhibitors (5) 5
map kinase (5) 5
melanoma - enzymology (5) 5
melanoma - immunology (5) 5
melanoma - therapy (5) 5
protein kinase inhibitors - therapeutic use (5) 5
tumor microenvironment (5) 5
animal models (4) 4
antigens (4) 4
apoptosis - drug effects (4) 4
care and treatment (4) 4
cell survival (4) 4
drug-resistance (4) 4
extracellular signal-regulated kinase (4) 4
gene expression regulation, neoplastic - drug effects (4) 4
immunohistochemistry (4) 4
in-vitro (4) 4
malignant melanoma (4) 4
mechanisms (4) 4
medicine, research & experimental (4) 4
mice, inbred nod (4) 4
molecular targeted therapy (4) 4
open-label (4) 4
pembrolizumab (4) 4
phenotype (4) 4
physiological aspects (4) 4
proteins (4) 4
raf inhibition (4) 4
science (4) 4
signal transduction (4) 4
targeted therapy (4) 4
xenografts (4) 4
adjuvant therapy (3) 3
antigens, cd - metabolism (3) 3
b-raf (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 06/2017, Volume 546, Issue 7658, pp. 431 - 435
Therapies that target signalling molecules that are mutated in cancers can often have substantial short-term effects, but the emergence of resistant cancer... 
METASTATIC MELANOMA | BRAF INHIBITOR | SUBPOPULATIONS | CHROMATIN | MULTIDISCIPLINARY SCIENCES | SINGLE MAMMALIAN-CELLS | STATE | MECHANISMS | MUTATIONS | VEMURAFENIB | PLASTICITY | Transcription, Genetic - drug effects | Humans | Male | Transcription Factor AP-1 - metabolism | DNA-Binding Proteins - metabolism | Melanoma - genetics | Female | Indoles - pharmacology | Epigenesis, Genetic - drug effects | Gene Expression Regulation, Neoplastic - drug effects | SOXE Transcription Factors - deficiency | Single-Cell Analysis | Cellular Reprogramming - genetics | ErbB Receptors - metabolism | In Situ Hybridization, Fluorescence | Nuclear Proteins - metabolism | Signal Transduction - genetics | Melanoma - pathology | Sulfonamides - pharmacology | Cellular Reprogramming - drug effects | Transcription Factors - metabolism | Xenograft Model Antitumor Assays | Genetic Markers - drug effects | Vemurafenib | Drug Resistance, Neoplasm - genetics | Animals | Signal Transduction - drug effects | Genetic Markers - genetics | Cell Line, Tumor | Oncogene Protein p65(gag-jun) - metabolism | Drug Resistance, Neoplasm - drug effects | SOXE Transcription Factors - genetics | Antimitotic agents | Cell interaction | Dosage and administration | Antineoplastic agents | Drug resistance | Observations | Health aspects | Subpopulations | Transcription factors | Substance abuse treatment | Variability | Activator protein 1 | Melanoma | Genomes | Kinases | Gene expression | Sox10 protein | Signal transduction | Signaling | Converting | Population | Mutation | Differentiation | Deoxyribonucleic acid--DNA | Cancer | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2017, Volume 23, Issue 12, pp. 3097 - 3108
Purpose: PARP inhibition (PARPi) has modest clinical activity in recurrent BRCA-mutant (BRCA(MUT)) high-grade serous ovarian cancers (HGSOC). We hypothesized... 
OLAPARIB | THERAPY | RANDOMIZED PHASE-2 | CHK1 | ONCOLOGY | PHOSPHORYLATION | SYNTHETIC LETHALITY | CELL-CYCLE | CHECKPOINT | REPLICATION FORK COLLAPSE | ATR | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Phthalazines - administration & dosage | Pyrimidines - administration & dosage | Humans | Checkpoint Kinase 1 - antagonists & inhibitors | Ovarian Neoplasms - pathology | Molecular Targeted Therapy | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Drug Synergism | Ovarian Neoplasms - genetics | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Sulfoxides - administration & dosage | Pyrazoles - administration & dosage | Animals | Ataxia Telangiectasia Mutated Proteins - antagonists & inhibitors | Cell Line, Tumor | Genomic Instability - drug effects | Female | Cell Proliferation - drug effects | Mice | Ovarian Neoplasms - drug therapy | Ovarian carcinoma | G2 phase | Genomes | Ovarian cancer | Genomic instability | Quality | Cell cycle | Xenografts | Remission | Inhibition | Cell survival | Stability | BRCA1 protein | Colonies | CHK1 protein | Regression | Poly(ADP-ribose) polymerase | Breast cancer | Stability analysis | Regression analysis | Survival | Experimental design | Cell death | Aberration | Chromosome aberrations | Cancer | Apoptosis | Index Medicus
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 05/2016, Volume 126, Issue 5, pp. 1834 - 1856
Targeting multiple components of the MAPK pathway can prolong the survival of patients with BRAF(V600E) melanoma. This approach is not curative, as some... 
MEDICINE, RESEARCH & EXPERIMENTAL | OXIDATIVE-PHOSPHORYLATION | CELLS | ONCOGENE | MELANOMA | MEK INHIBITION | PGC1-ALPHA | IMPROVED SURVIVAL | BRAF | STRESS | VEMURAFENIB | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Guanidines - pharmacology | Male | Neoplasm Proteins - antagonists & inhibitors | Mitochondrial Proteins - genetics | Extracellular Signal-Regulated MAP Kinases - metabolism | Neoplasm Proteins - metabolism | Extracellular Signal-Regulated MAP Kinases - genetics | DNA-Binding Proteins - metabolism | Mitochondria - genetics | Melanoma - genetics | Mitochondrial Proteins - metabolism | Female | HSP90 Heat-Shock Proteins - genetics | Neoplasm Proteins - genetics | Melanoma - metabolism | Mitochondria - metabolism | Melanoma - pathology | Mitochondria - pathology | Transcription Factors - genetics | DNA-Binding Proteins - genetics | Lactams, Macrocyclic - pharmacology | Transcription Factors - metabolism | Animals | Mitochondrial Dynamics - drug effects | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Melanoma - drug therapy | HSP90 Heat-Shock Proteins - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Mitochondrial biogenesis | Research | Drug resistance | Analysis | Extracellular signal-regulated kinases | Genes | Genomics | Melanoma | Heat shock proteins | Development and progression | Biosynthesis | Mitochondrial DNA | Genetic transcription | Phosphorylation | Genomes | Kinases | Metabolism | Gene expression | Studies | Protein folding | Tumors | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Nature, ISSN 0028-0836, 10/2017, Volume 550, Issue 7674, pp. 133 - 136
Targeted BRAF inhibition (BRAFi) and combined BRAF and MEK inhibition (BRAFi and MEKi) therapies have markedly improved the clinical outcomes of patients with... 
METASTATIC MELANOMA | MEK | EPITHELIAL-CELLS | PHOSPHORYLATION | PATHWAY | RAF | P21-ACTIVATED-KINASE-1 | MULTIDISCIPLINARY SCIENCES | KINASE | MECHANISMS | THERAPIES | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | p21-Activated Kinases - antagonists & inhibitors | Melanoma - enzymology | JNK Mitogen-Activated Protein Kinases - metabolism | Mitogen-Activated Protein Kinase Kinases - metabolism | Melanoma - genetics | Proto-Oncogene Proteins c-raf - chemistry | Female | beta Catenin - chemistry | Phosphorylation - drug effects | p21-Activated Kinases - genetics | JNK Mitogen-Activated Protein Kinases - chemistry | Enzyme Activation - drug effects | p21-Activated Kinases - metabolism | beta Catenin - metabolism | Proto-Oncogene Proteins c-raf - metabolism | Mitogen-Activated Protein Kinase Kinases - chemistry | Drug Resistance, Neoplasm - genetics | Animals | MAP Kinase Signaling System - drug effects | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Mutation | Drug Resistance, Neoplasm - drug effects | Melanoma | Physiological aspects | Cellular signal transduction | Drug resistance | Observations | Health aspects | Mitogen-activated protein kinases | TOR protein | Therapy | Phosphorylation | Activation | Metastasis | Drug development | Kinases | Cancer therapies | Metastases | Proteins | β-catenin | Signal transduction | Inhibition | Extracellular signal-regulated kinase | MAP kinase | JNK protein | Patients | Signaling | Protein arrays | Molecular modelling | Biopsy | Cell lines | Apoptosis | Index Medicus
Journal Article
Cancer Cell, ISSN 1535-6108, 06/2013, Volume 23, Issue 6, pp. 811 - 825
Despite success with BRAFV600E inhibitors, therapeutic responses in patients with metastatic melanoma are short-lived because of the acquisition of drug... 
Journal Article
Cell Reports, ISSN 2211-1247, 09/2013, Volume 4, Issue 6, pp. 1090 - 1099
Journal Article
The Lancet Oncology, ISSN 1470-2045, 09/2019, Volume 20, Issue 9, pp. 1239 - 1251
Pembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a standard of care in the... 
Ipilimumab | Analysis | Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 12/2017, Volume 8, Issue 1, pp. 1 - 16
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2013, Volume 8, Issue 3, pp. e59588 - e59588
Journal Article
Journal Article
MEDICINE, ISSN 0025-7974, 07/2019, Volume 98, Issue 28, pp. e16328 - e16328
Recently, the effectiveness of novel immune checkpoint inhibitors and BRAF-directed therapies has been demonstrated in advanced melanoma trial populations.... 
SURVIVAL | medical record systems computerized | EFFICACY | COMBINED NIVOLUMAB | melanoma | BRAF | MALIGNANT-MELANOMA | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL |